ENTRY       D11027                      Drug
NAME        Ropeginterferon alfa-2b (INN);
            Ropeginterferon alfa-2b (genetical recombination) (JAN);
            Ropeginterferon alfa-2b-njft;
            Besremi (TN)
PRODUCT     BESREMI (PharmaEssentia USA)
SEQUENCE    PCDLPQTHSL GSRRTLMLLA QMRRISLFSC LKDRHDFGFP QEEFGNQFQK AETIPVLHEM
            IQQIFNLFST KDSSAAWDET LLDKFYTELY QQLNDLEACV IQGVGVTETP LMKEDSILAV
            RKYFQRITLY LKEKKYSPCA WEVVRAEIMR SFSLSTNLQE SLRSKE
            (Disulfide bridge: 2-99, 30-139)
  TYPE      Peptide
CLASS       Immunological agent
             DG01752  Interferone
REMARK      Therapeutic category: 4291
            ATC code: L03AB15
            Product: D11027<JP/US>
EFFICACY    Antineoplastic, Antiviral
  DISEASE   Polycythemia vera [DS:H00012]
TARGET      IFNAR1 [HSA:3454] [KO:K05130]
            IFNAR2 [HSA:3455] [KO:K05131]
  PATHWAY   hsa04060(3454+3455)  Cytokine-cytokine receptor interaction
            hsa04620(3454+3455)  Toll-like receptor signaling pathway
            hsa04630(3454+3455)  JAK-STAT signaling pathway
            hsa04650(3454+3455)  Natural killer cell mediated cytotoxicity
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L03 IMMUNOSTIMULANTS
               L03A IMMUNOSTIMULANTS
                L03AB Interferons
                 L03AB15 Ropeginterferon alfa-2b
                  D11027  Ropeginterferon alfa-2b (INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunostimulants
               Interferons
                Ropeginterferon Alfa-2b
                 D11027  Ropeginterferon alfa-2b (INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D11027  Ropeginterferon alfa-2b (INN); Ropeginterferon alfa-2b (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG01752  Interferone
               D11027  Ropeginterferon alfa-2b
            Drug classes [BR:br08332]
             Immunological agent
              DG01752  Interferone
               D11027  Ropeginterferon alfa-2b
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interferon receptors
                IFNAR1
                 D11027  Ropeginterferon alfa-2b (INN) &lt;JP/US&gt;
                IFNAR2
                 D11027  Ropeginterferon alfa-2b (INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11027
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11027
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11027
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11027
DBLINKS     CAS: 1335098-50-4
            PubChem: 350078346
///
